Supernus Pharmaceuticals Inc
SUPN
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.37B
Close$
$76.56
88.1% upside
Current Fair Value
88.1% upsideUndervalued by 88.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.37 Billion |
|---|---|
| Enterprise Value | $2.23 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.68 |
| Beta | 0.55 |
| Outstanding Shares | 58,070,000 |
Return
| Return on Equity | -10.66% |
|---|---|
| Return on Assets | -7.69% |
| Return on Invested Capital | -13.85% |
Valuation & Multiples
| P/E Ratio | -21.18 |
|---|---|
| PEG | 5.89 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 2.39 |
| Enterprise Value to Revenue | 0.01 |
| Enterprise Value to EBIT | -14.9 |
| Enterprise Value to Net Income | -21 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$0.42
Average shareholder expectationRevenue Estimate
$205.31 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$0.49
Average shareholder expectationRevenue Estimate
$217.56 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 642.52% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.38%▼ 103.65% |
|---|---|
| Total Invested | $34.42M▼ 98.79% |
| Investors Holding | 51▼ 289.00% |
ESG Score
No data
About Supernus Pharmaceuticals Inc
778 employees
CEO: Jack Khattar Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research, development, and market introduction of therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed medica...